ArticleFrontiers in immunology2025
A retrospective efficacy and safety study of pembrolizumab/cetuximab neoadjuvant therapy in locally advanced hypopharyngeal cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The primary objective of this study was to retrospectively assess the efficacy and safety profiles of two neoadjuvant regimens combining either pembrolizumab or cetuximab with paclitaxel and cisplatin in patients with locally advanced hypopharyngeal cancer (LAHPC). Methods: LAHPC patients who received surgical resection at our hospital between August 2022 and February 2024 were enrolled in the study. All patients received neoadjuvant treatment before surgery and postoperative adjuvant therapy. They were categorized into two groups based on the neoadjuvant regimen: the paclitaxel + cisplatin + pembrolizumab (TP + PEMBRO) group and the paclitaxel + cisplatin + cetuximab (TP + CETUX) group. We evaluated various parameters including treatment response rate, adverse effects, surgical modalities, and survival outcomes for both groups. Results: A total of 32 LAHPC patients were enrolled into the study, with 16 patients in each group. The TP + PEMBRO group demonstrated a significantly superior objective response rate (ORR) of neoadjuvant treatment compared to the TP + CETUX group (87.5% vs 68.75%, P < 0.05). In terms of surgical procedures, the TP + PEMBRO group exhibited a higher proportion of minimally invasive surgeries (87.5% vs 56.25%, P < 0.05), and both the tracheotomy rate and indwelling gastric tube rate were relatively lower in this group. Regarding patient prognosis, the 1-year overall survival (OS) rate in the TP + PEMBRO group was 100%, and the 1-year relapse-free survival (RFS) rate was 92.31%. In contrast, the TP + CETUX group had a 1-year OS rate of 93.75% and a 1-year RFS rate of 81.25%. There was no significant disparity in adverse events between the two groups, and no grade 3-4 severe adverse events occurred. Conclusion: The neoadjuvant TP regimen integrating pembrolizumab or cetuximab was associated with higher transoral surgery (TOS) rates and laryngeal preservation rates. Notably, the TP + PEMBRO regimen outperformed the TP + CETUX regimen in terms of treatment response rate and the proportion of minimally invasive surgeries, suggesting a novel and efficacious neoadjuvant treatment for LAHPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.